Noble Life Science Partners, a division of Noble Financial Capital Markets (Noble) today announced that the company has formed a strategic partnership agreement with Boston-based JSB-Partners (JSB).

For decades, the business of radio and television has been a reliable money-maker for investors large and small. However, the advent of the Web and mobile delivery platforms, plus the explosion in streaming media enterprises such as Netflix and Pandom, have made this once-simple investment opportunity complicated
and confusing for non-technical capitalists.

Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the closing of its previously announced underwritten public offering of 24,358,974 shares of common stock, and warrants to purchase an aggregate of 12,179,487 shares of common stock at an exercise price of $2.08 per share.

Noble Financial Capital Markets (Noble) today announced the launch of its new corporate website. The majority of photography and inspiration for the site comes from the location of the company's 11th Annual Equity / Investor Conference: Club Med, located in Sandpiper Bay, South Florida.

Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the closing of its previously announced underwritten public offering of 24,358,974 shares of common stock, and warrants to purchase an aggregate of 12,179,487 shares of common stock at an exercise price of $2.08 per share.

For Martha Stewart, a very good thing appears about to happen — and her stock price is soaring to its highest price since mid-May 2010. It closed at $6.36 on Monday, up 14 percent on the day.

(Reuters) - Western Digital Corp, the world's No. 1 hard-disk drive maker, reported second-quarter results slightly ahead of Wall Street expectations on strong demand for its solid-state drives from enterprise customers.

Conkwest, Inc., the Natural Killer Cell Company of the West, developing the proprietary Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an immuno-oncology therapeutic, announces that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, has entered into a definitive agreement to purchase approximately $48 million of the Company's Class A Common Stock.